Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta

Bone

Volumn 35, Issue 1, 2004, Pages 231-234

  Munns, Craig F ^a   Rauch, Frank ^a   Mier, Richard J ^b   Glorieux, Francis H ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b Shriners Hospital for Children   (United States)

^c SHRINERS HOSPITAL FOR CHILDREN   (Canada)

Author keywords

Bisphosphonates; Osteogenesis imperfecta; Respiratory distress; Side effects

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; GLUCOCORTICOID; PAMIDRONIC ACID; SALBUTAMOL;

ANAMNESIS; ARTICLE; BRADYCARDIA; CASE REPORT; CAUSE OF DEATH; CLINICAL FEATURE; CYTOKINE RELEASE; DISEASE SEVERITY; FEVER; HEMODYNAMICS; HUMAN; INFANT; LABORATORY TEST; MALE; OSTEOGENESIS IMPERFECTA; OXYGEN THERAPY; PRESCHOOL CHILD; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; TACHYPNEA; WHEEZING;

DIPHOSPHONATES; HUMANS; INFANT; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; MALE; OSTEOGENESIS IMPERFECTA; RESPIRATORY INSUFFICIENCY;

EID: 2942702068     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2004.03.008     Document Type: Article

References (17)

1. Astrom E., Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch. Dis. Child. 86:2002;356-364
2. Byers P., Cole W. Osteogenesis imperfecta. Royce P.M., Steinmann B. Connective Tissue and Its Heritable Disorders. 2002;385-430 Wiley-Liss, New York
3. Engelbert R.H., Uiterwaal C.S., Gulmans V.A., Pruijs H.E., Helders P.J. Osteogenesis imperfecta: profiles of motor development as assessed by a postal questionnaire. Eur. J. Pediatr. 159:2000;615-620
4. Glorieux F.H. The use of bisphosphonates in children with osteogenesis imperfecta. J. Pediatr. Endocrinol. Metab. 14(Suppl. 6):2001;1491-1495
5. Glorieux F.H., Bishop N.J., Plotkin H., Chabot G., Lanoue G., Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N. Engl. J. Med. 339:1998;947-952
6. Gutteridge D.H., Retallack R.W., Ward L.C., Stuckey B.G., Stewart G.O., Prince R.L., et al. Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study. Bone. 19:1996;387-394
7. Hamill P.V., Drizd T.A., Johnson C.L., Reed R.B., Roche A.F., Moore W.M. Physical growth: National Center for Health Statistics percentiles. Am. J. Clin. Nutr. 32:1979;607-629
8. Montpetit K., Plotkin H., Rauch F., Bilodeau N., Cloutier S., Rabzel M., et al. Rapid increase in grip force after start of pamidronate therapy in children and adolescents and severe osteogenesis imperfecta. Pediatrics. 111:2003;e106-e111
9. Pecherstorfer M., Jilch R., Sauty A., Horn E., Keck A.V., Zimmer-Roth I., et al. Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations. J. Bone Miner. Res. 15:2000;147-154
10. Plotkin H., Rauch F., Bishop N.J., Montpetit K., Ruck-Gibis J., Travers R., et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J. Clin. Endocrinol. Metab. 85:2000;1846-1850
11. Rauch F., Plotkin H., Travers R., Zeitlin L., Glorieux F.H. Osteogenesis imperfecta types I, III and IV: effect of pamidronate therapy on bone and mineral metabolism. J. Clin. Endocrinol. Metab. 88:2003;986-992
12. Rauch F., Plotkin H., Zeitlin L., Glorieux F.H. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J. Bone Miner. Res. 18:2003;610-614
13. Rolla G., Bucca C., Brussino L. Bisphosphonate-induced bronchoconstriction in aspirin-sensitive asthma. Lancet. 343:1994;426-427
14. Singer R.B., Ogston S.A., Paterson C.R. Mortality in various types of osteogenesis imperfecta. J. Insur. Med. 33:2001;216-220
15. Thiebaud D., Sauty A., Burckhardt P., Leuenberger P., Sitzler L., Green J.R., et al. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif. Tissue Int. 61:1997;386-392
16. Zacharin M., Bateman J. Pamidronate treatment of osteogenesis imperfecta - Lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. J. Pediatr. Endocrinol. Metab. 15:2002;163-174
17. Zeitlin L., Rauch F., Plotkin H., Glorieux F.H. Height and weight development during long-term therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III and IV. Pediatrics. 111:2003;1030-1036